The RET fusion-targeted therapy market is set for strong expansion, driven by growing awareness of the oncogenic role of RET gene fusions and ...
The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular franchises. For example, sales of Tagrisso, an EGFR inhibitor for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results